Elon Musk’s brain-computer interface company Neuralink is preparing for a major expansion, announcing plans to begin high-volume production of its brain implant devices and transition to a fully automated surgical procedure by 2026. The announcement was made by Musk in a post on the social media platform X, highlighting the company’s long-term vision to scale its neurotechnology and make implantation faster, safer, and more accessible.
Neuralink’s brain implant technology is designed to help people with severe neurological conditions, including spinal cord injuries and paralysis, by enabling direct communication between the brain and external devices. The implant allows users to control digital tools using their thoughts, opening new possibilities for restoring independence and improving quality of life. According to previously shared updates, the first patient implanted with the device has successfully used it to play video games, browse the internet, post on social media, and control a laptop cursor without physical movement.
The company began human trials of its brain-computer interface in 2024 after resolving safety concerns raised by the U.S. Food and Drug Administration. The FDA had initially rejected Neuralink’s application in 2022, citing potential risks, but later approved the trials after additional safeguards were implemented. This marked a significant milestone for the company and the broader neurotechnology industry.
In September, Neuralink revealed that 12 people worldwide with severe paralysis had already received its brain implants. These individuals were reportedly using the technology to control both digital and physical tools purely through thought, demonstrating the real-world potential of brain-computer interfaces. The company has also attracted strong investor interest, securing $650 million in a funding round completed in June, further supporting its research, development, and manufacturing goals.
While Neuralink did not immediately respond to a request for comment, Musk’s statement suggests the company is moving toward large-scale deployment. If successful, high-volume production and fully automated surgical implantation could significantly accelerate adoption of brain implant technology, positioning Neuralink as a leader in the rapidly evolving field of neural interfaces and medical innovation.


NASA's Artemis II Crew Arrives in Florida for Historic Moon Mission
SMC Corp Stock Surges as Palliser Capital Pushes for Major Share Buyback
Neuralink Expands Brain Implant Trials with 12 Global Patients
Trump Signs Executive Order to Boost AI Research in Childhood Cancer
Air Liquide Q1 Revenue Misses Estimates Amid Currency and Energy Headwinds
T-Mobile Beats Q1 Earnings Expectations on Strong Postpaid Growth
Trump Administration to Launch Autism Initiatives Targeting Acetaminophen Use and New Treatment Options
U.S. Raises Alarm Over Chinese AI Firms’ Alleged IP Theft Through Model Distillation
TSMC Exits Arm Holdings with $231 Million Share Sale Amid Strategic Portfolio Shift
Meta Raises 2026 Capex Outlook Amid AI Spending Surge, Shares Drop After Earnings
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth
Google Secures Pentagon AI Deal for Classified Projects
Berkshire Hathaway Q1 Earnings Jump 18% as Greg Abel Signals Disciplined Growth Strategy
Chinese Chip Stocks Surge on AI Boom and Domestic Tech Push
Taiwan Court Fines Tokyo Electron Unit $4.78M in Major TSMC Trade Secrets Case 



